Ona Therapeutics Raises $86.6 Million Series B co-led by Columbus Venture Parrners and Mérieux Equity Partners to Advance First-in-Class ADCs into Clinical Development

by Columbus Venture Partners

The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life...

Read more

CDTI invests in the InceptionBio fund, launched by Ysios to support the creation of biotech companies

by CDTI Innovación

InceptionBio will focus on identifying, developing, and building new companies based on excellent science, with a special emphasis on Spain. The fund will primarily invest in technology transfer proje...

Read more

UCB agrees to acquire Neurona Therapeutics, a Ysios Capital portfolio company, in a deal worth up to $1.15 billion

by Ysios Capital

UCB, a global biopharmaceutical company, has announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, an Ysios Capital portfolio company, including...

Read more

Adcendo, an Ysios Capital portfolio company, Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

by Ysios Capital

The financing round was led by Jeito Capital, with participation from additional new investors Vida Ventures, BPI France, and EIFO (Export and Investment Fund of Denmark), as well as all existing inve...

Read more

Ysios Capital launches InceptionBio with a target size of €100 million

by Ysios Capital

InceptionBio, Ysios’ fourth vehicle, will focus on identifying and building companies based on cutting-edge science, with a special emphasis on Spain. The fund will invest in technology transfer pro...

Read more

Xeltis, an Ysios portfolio company, secures nearly €50m from the EIB and existing shareholders to advance aXess

by Ysios Capital

It has secured €37.5m from the EIB, supported under the European Commission’s Invest EU programme, and €10m from existing investors, including EQT, investing from its LSP Health Economics Fund 2...

Read more

CDTI Innovación invests in Ona Therapeutics, together with five co-investors

by CDTI Innovación

Ona Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...

Read more

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

by Asabys Partners

The Series B financing was co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB ...

Read more

ReproNovo raises $65 million Series A financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and women’s health

by Ysios Capital

ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced the successful closing of a $65 million Series A financing round. The...

Read more

Ysios Capital y Andbank se alían para lanzar el fondo Telescope Biotech Fund

by Ysios Capital

La inversión del Telescope Biotech Fund sigue una metodología altamente especializada, con una selección cuidada y rigurosa de compañías biotech y farmacéuticas. La firma identifica las tecnolog...

Read more

Ysios Capital participates in $135 million Series B round of Adcendo ApS

by Ysios Capital

The financing round was led by TCGX, with participation from new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), a...

Read more

AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences

by Ysios Capital

AELIX Therapeutics, a biopharmaceutical company backed by Ysios Capital based in Barcelona, Spain, that focuses on HIV vaccine development, today announced that Gilead Sciences, Inc. (Nasdaq: GILD), b...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Citring closes a €920,000 funding roun...

by Faraday Venture Partners

Citring began operations in late 2017 and passed through Lanzadera, on...

Photos Stream